US EditionIASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)
Summary by The Victoria Advocate
5 Articles
5 Articles
Longview News-Journal+2 Reposted by 2 other sources
IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy of Neurology (EAN)
SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that results from an investigator-initiated…
Málaga HoyReposted by 
El Día de Córdoba
El Día de CórdobaOne study reveals that Andalusia presents one of the lowest rates in Spain Researchers encourage to consider whether it is due to real factors or inequalities in diagnosis and its approach
Coverage Details
Total News Sources5
Leaning Left1Leaning Right0Center2Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 33%
C 67%
Factuality
To view factuality data please Upgrade to Premium
